ARANZ Medical Raises NZ$5mil New Equity Financing
ARANZ Medical Raises NZ$5mil New Equity Financing

ARANZ Medical Limited announces the closing of a NZ$5million equity financing.

TUMI Partners with SmartGift on Digital Giving Back Experience
TUMI Partners with SmartGift on Digital Giving Back Experience

TUMI teamed up with SmartGift to let recipients of a TUMI SmartGift express their gratitude with a donation to St. Jude Children’s Research Hospital® this season.

ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European Medicines Agency (EMA) has granted PRIME...

Actuate Therapeutics Opens Phase 1 / 2 Clinical Study of 9-ING-41 in Patients with Refractory Cancers
Actuate Therapeutics Opens Phase 1 / 2 Clinical Study of 9-ING-41 in Patients with Refractory Cancers

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3ß)...

Indivior Provides Legal and Trading Update; Confirms Launch of PERSERIS™ and Key Elements of Contingency Plan
Indivior Provides Legal and Trading Update; Confirms Launch of PERSERIS™ and Key Elements of Contingency Plan

Indivior PLC (the "Company") with today's announcement and accompanying supplement published on its website (http://www.indivior.com) is:

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of Verzenio® (abemaciclib)...

Apotheka Systems Inc. Patents Patient Identity Validation On Blockchain
Apotheka Systems Inc. Patents Patient Identity Validation On Blockchain

On Tuesday December 18th Apotheka Systems Inc. announced the submittal of proprietary technology patents to the US Patent Office. This marks a milestone in the Healthcare EHR industry by making Apotheka a first if not the...

Indivumed Announces an International Partnership With IMCB to Establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology
Indivumed Announces an International Partnership With IMCB to Establish an Asian-Centric Multiomics Cancer Database for Personalized Oncology

Indivumed GmbH today announced the launch of the "Cancer Library Initiative", an operation to further accelerate precision diagnostics and personalised treatment for cancer patients, in collaboration with A*STAR's...

Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting migraine and...

McLaren Greater Lansing breaks ground on new hospital
McLaren Greater Lansing breaks ground on new hospital

Officials from McLaren Health Care and Michigan State University today held a ceremonial groundbreaking at University Corporate Research Park, the next step in building a new $450 million health care campus adjacent to the...

Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease
Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease

Neurotrope Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that data from its Phase 2,...

Balance 3H Plus Expands to New York City
Balance 3H Plus Expands to New York City

Harrison-based Balance 3H Plus, a leading, doctor-supervised total health program that provides hormonal balance solutions for women 40 and older, has expanded to New York City. The new office is located at 12 East 52nd...

Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy in the prescribing information for Betaseron® (Interferon beta 1b, IFNß-1b), which is...

DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and Distinguished Scientist effective December 31, 2018.  Dr. Theeuwes has been scaling back his activities in...

Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease
Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease

Neurotrope Inc. (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that data from its Phase 2,...

Balance 3H Plus Expands to New York City
Balance 3H Plus Expands to New York City

Harrison-based Balance 3H Plus, a leading, doctor-supervised total health program that provides hormonal balance solutions for women 40 and older, has expanded to New York City. The new office is located at 12 East 52nd...

Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy in the prescribing information for Betaseron® (Interferon beta 1b, IFNß-1b), which is...

DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and Distinguished Scientist effective December 31, 2018.  Dr. Theeuwes has been scaling back his activities in...

Diabeloop at CES in Las Vegas to Present Its Groundbreaking Automated Insulin Delivery System for Type 1 Diabetes
Diabeloop at CES in Las Vegas to Present Its Groundbreaking Automated Insulin Delivery System for Type 1 Diabetes

Making its second appearance at CES, the world's leading technology event, on 8-11 January 2019 at Las Vegas, the Grenoble-based firm Diabeloop, invited by the CEA, will present its plan to adapt its machine-learning...

Connect 

CareCredit Now Integrated Into Henry Schein's Dental And Veterinary Practice Management Software Solutions
CareCredit Now Integrated Into Henry Schein's Dental And Veterinary Practice Management Software Solutions

Henry Schein, Inc. (Nasdaq: HSIC) and CareCredit, a Synchrony (NYSE:SYF) solution and a leading provider of patient financing, today announced the integration of CareCredit's financing tool into Henry Schein's...

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted...

Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis

Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira®...

RenalSense Conducts Pilot Study at University of Pittsburgh Medical Center
RenalSense Conducts Pilot Study at University of Pittsburgh Medical Center

RenalSense® announced today that it is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of ??Professor John Kellum....

Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF
Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF

Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@TMC in Houston, Texas, announced that the Investigational New Drug (IND) application for...

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Incyte (NASDAQ:INCY) today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three...

FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one...

Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety
Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety

Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription medicines in all pain related indications. The agreement also entails an...

Elsevier and Leiden University Libraries Establish Fellowship Program for Digital Scholarship
Elsevier and Leiden University Libraries Establish Fellowship Program for Digital Scholarship

Elsevier collaborates with Leiden University Libraries' Centre for Digital Scholarship and Scaliger Institute to enhance the study of digital collections  Elsevier, the information analytics business specializing in...

Vast Therapeutics Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51
Vast Therapeutics Announces Funding from Cystic Fibrosis Foundation for Further Development of BIOC51

Vast Therapeutics, Inc., (the Company), a preclinical stage pharmaceutical company focused on delivering nitric oxide (NO) in a synthetically derived powder-based form, announced today that the Company has received an...

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled
EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, announced today that it has fully enrolled the REVERSE-SD study, a placebo controlled, Phase 2b trial of the investigational drug neflamapimod in...

Certified PAs at the Forefront of 2019 Health Care Trends
Certified PAs at the Forefront of 2019 Health Care Trends

As 2018 comes to a close, clear trends in health care are emerging that will increasingly require the services of Certified PAs. These include significant changes in technology, scope of practice, and specialization that...

Sixteen Years in the Making, National Geographic Unveils a Behind-the-Scenes Look at the Creation of the Highest-Quality Imagery of a Human Body in Existence
Sixteen Years in the Making, National Geographic Unveils a Behind-the-Scenes Look at the Creation of the Highest-Quality Imagery of a Human Body in Existence

Today, National Geographic releases "The Immortal Corpse," a story, 16-years in the making, that chronicles the life, death and digital resurrection of Susan Potter and her impact on the future of medicine for decades to...

Colin Zhu, DO, Publishes His First Book, "Thrive Medicine: How to Cultivate Your Desires and Elevate Your Life"
Colin Zhu, DO, Publishes His First Book, "Thrive Medicine: How to Cultivate Your Desires and Elevate Your Life"

Are we living a default life? Or are we living our best lives? So much of society tells us to go to school, find a job, have a family, and then we pass on. Not to sound morbid, but was that all there is? Perhaps we can...

Scientists Create Most Accurate Tool Yet Developed To Predict Asthma in Young Children
Scientists Create Most Accurate Tool Yet Developed To Predict Asthma in Young Children

Scientists at Cincinnati Children's Hospital Medical Center have created and tested a decision tool that appears to be the most accurate, non-invasive method yet developed to predict asthma in young children.

US News 

Local News 

World News